Jazz Pharmaceuticals plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Jazz Pharmaceuticals plc
While Defitelio is not authorized in the EU for the prevention of veno-occlusive disease (VOD), the European Medicines Agency wants health professionals to be informed about the results of a recent study in which the drug showed no benefit in this indication.
The Ireland-headquartered firm will advance the candidate into US and EU narcolepsy studies as part of its pipeline diversification project as portfolio products are set to lose their patent exclusivity.
AstraZeneca licenses bispecific cancer antibody candidate from Harbour Biomed. Regeneron seeks new approach to gene therapy delivery in deal with ViGeneron.
The Massachusetts-based biotech’s fundraise will be used to discover and develop molecular glues with an initial focus on cancer targets.
- Contract Manufacturing Organization
- Drug Discovery Tools
- Other Names / Subsidiaries
- Alizé Pharma II
- Azur Pharma Public Limited Company
- Cavion, Inc.
- Cavion LLC (Tau Therapeutics LLC
- Xdynia LLC)
- Celator Pharmaceuticals, Inc.
- Gentium S.p.A.
- GW Pharmaceuticals plc
- Jazz Pharmaceuticals Ireland Limited
- Orphan Medical, Inc.